ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1427

Low Prevalence of Sarcopenic Obesity in Rheumatoid Arthritis Patients with Moderate Clinical Activity

Nina Tello-Winniczuk1, David Vega-Morales2, Mario Garza-Elizondo1, Dionicio Galarza-Delgado1, Jorge Esquivel-Valerio1, Octavio Ilizaliturri-Guerra3 and Jorge Rodriguez-Olivo4, 1Departamento de Medicina Interna del Hospital Universitario “Dr. José Eleuterio González”, Universidad Autónoma de Nuevo León, Servicio de Reumatología, Departamento de Medicina Interna del Hospital Universitario “Dr. José Eleuterio González”, Universidad Autónoma de Nuevo León, Monterrey, Mexico, 2Rheumatology, Hospital Universitario UANL, Monterrey, Mexico, 3Departamento de Medicina Interna del Hospital Universitario “Dr. José Eleuterio González”, Universidad Autónoma de Nuevo León, Departamento de Medicina Interna del Hospital Universitario “Dr. José Eleuterio González”, Universidad Autónoma de Nuevo León, Monterrey, Mexico, 4Servicio de Reumatología, Departamento de Medicina Interna del Hospital Universitario “Dr. José Eleuterio González”, Universidad Autónoma de Nuevo León, Monterrey, Mexico

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: obesity, rheumatoid arthritis (RA) and sarcopenia

  • Tweet
  • Email
  • Print
Session Information

Title: Rheumatoid Arthritis - Clinical Aspects (ACR): Comorbidities, Treatment Outcomes and Mortality

Session Type: Abstract Submissions (ACR)

Background/Purpose .

Rheumatoid arthritis is an inflammatory systemic disease that leads to body composition alterations. Objective: The aim of our study was to identify the prevalence of sarcopenia, obesity and sarcopenic obesity in our population.

Methods .

We performed an observational, analytical study with 101 rheumatoid arthritis patients. Demographic, clinical and biochemical variables were recorded. Studies of body composition by dual X-ray absorciometry were performed. We took into account different definitions to determine body composition alterations (Table 1).

Results .

Ninety-seven (96%) patients were female, the rest of baseline characteristics are shown in Table 2. The mean age of our patients was 50.5 years (SD 12.3). The mean body mass index was 29.29 kg/m2 (5.4 SD). According to the World Health Organization classification of body mass index (BMI), 24 (23.8 %) patients had normal weight, 38 (37.6%) were overweight and 39 (38.6 %) some degree of obesity. According to the BMI adjusted for rheumatoid arthritis, 13 patients (12.9 %) were normal, 34 (33.7 %) overweight and 54 (53.5 %) obese. Ten patients had sarcopenia (9.9 %). Six patients (5.9 %) had sarcopenic obesity. Patients with obesity by dual X-ray absorciometry were 83 (82.2 %). Among clinical and para-clinical variables, the only significant association with sarcopenia was a higher score in the Health Assessment Questionnaire.

Conclusion .

The most prevalent body composition alteration in RA patients, were obesity. Sarcopenic obesity had a low prevalence, contrary to previous reports.


Disclosure:

N. Tello-Winniczuk,
None;

D. Vega-Morales,
None;

M. Garza-Elizondo,
None;

D. Galarza-Delgado,
None;

J. Esquivel-Valerio,
None;

O. Ilizaliturri-Guerra,
None;

J. Rodriguez-Olivo,
None.

  • Tweet
  • Email
  • Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/low-prevalence-of-sarcopenic-obesity-in-rheumatoid-arthritis-patients-with-moderate-clinical-activity/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology